SpyBiotech has declared that they've submitted a clinical trial request to the U.K. MHRA for SPYVLP01 assessment.

Merck has reported that the U.S. FDA is conducting a priority analysis on a fresh sBLA petitioning for authorization of KEYTRUDA, Merck’s anti-PD-1 treatment.

The Menarini Group,together with their fully owned subsidiary Stemline Therapeutics Inc., declared that ORSERDU® (elacestrant) has received authorisation from the European Commission.

Orchard Therapeutics, a renowned leader in gene therapy worldwide, reported that the U.S. FDA has approved the submission of their BLA for OTL-200.

Rani Therapeutics Holdings proclaimed the launch of a Phase 1 clinical investigation assessing the safety and tolerability of RT-111.

LAPIX Therapeutics, Inc. announced U.S. FDA clearance of its IND application. The approval enables Phase 1 trials for its leader compound, LPX-TI641, aimed at treating multiple sclerosis.

Revolution Medicines, Inc. has initiated Phase 1/1b trials for RMC-9805, a covalent, oral KRAS G12D inhibitor for RAS-dependent cancers and the first patient already dosed targeting KRAS G12D mutation-driven cancers.

Cerevance announced the start of their Phase 1 trial, with the first participant dosed to evaluate the safety, tolerability, and pharmacokinetics of CVN293.

ImmPACT Bio USA, Inc has publicized that the initial patient has received treatment in the Phase 1/2 trial of IMPT-314.

MRM Health NV has announced encouraging preliminary outcomes from its Phase 2a clinical study of MH002 against mild-to-moderate Ulcerative Colitis.

Drug Farm, currently in the clinical phase, has shared the news of the first participant in the Phase 1 clinical experiment, testing DF-003, receiving their initial dosage.

The study on Atrial Fibrillation using Abelacimab was prematurely ended by the Data Monitoring Committee due to a massive decrease in bleeding compared to a DOAC.